Tempest Therapeutics appoints Sheldon Mullins as VP, regulatory affairs

Tempest Therapeutics announced the appointment of Sheldon Mullins as Vice President, Regulatory Affairs. Mr. Mullins’ presence on the team builds upon the recent addition of Troy Wagner as Vice President of Quality Assurance, who brought additional late-stage experience to the company. Additionally, in connection with the plan to advance amezalpat into a pivotal study in first-line HCC patients and to reflect their roles in late-stage development, the titles of Darrin Bomba and Henry Johnson have been changed to Vice President, Development Operations and Vice President, CMC & Medicinal Chemistry, respectively. Prior to joining Tempest, he held regulatory leadership roles at Arrowhead Pharmaceuticals and Ardelyx.